Oxford Nanopore leaps 20% after stronger first half trading

Oxford Nanopore Technologies (ONT) shares surged 20% after the DNA and RNA testing group reported first-half 2025 revenue of approximately £105 million, exceeding analyst forecasts by 5% and growing 25% year-on-year. This strong performance, which outpaced its unchanged full-year growth guidance of 20-23%, was achieved despite a slight H1 gross margin dip due to one-off charges, with the full-year margin target of 59% maintained. The robust trading update signals operational momentum, driving significant share price appreciation.

Analysis

Oxford Nanopore Technologies (LSE:ONT) demonstrated robust top-line momentum in its first-half 2025 trading update, triggering a 20% share price increase. The company reported revenue of approximately £105 million, a significant 25% year-over-year increase (28% on a constant currency basis) that surpassed average analyst forecasts by 5%. This performance outpaced the company's full-year growth guidance of 20-23%. However, management's decision to maintain this full-year guidance, despite the strong first half, suggests an anticipated deceleration in growth for the second half of the year. Profitability metrics present a mixed picture; while the H1 gross margin is expected to dip slightly below the prior year's 58.8% due to a one-off inventory charge and FX headwinds, the company reaffirmed its full-year target of around 59%, indicating an expected margin recovery. The balance sheet shows a decline in cash and equivalents from £403.8 million to £337 million in the six-month period, a notable cash burn that warrants monitoring. While the stock has gained significantly year-to-date, it remains approximately 67% below its five-year peak, providing crucial context to the recent rally.

Key Decisions for Investors

• Investors should recognize the strong H1 revenue beat but critically question why full-year guidance was not raised, as this implies a potential slowdown in the second half.
• Monitor the company's ability to achieve its reaffirmed full-year gross margin target of 59%, as execution in H2 will be key to offsetting the first-half margin dip and validating operational control.
• The reduction in cash reserves by nearly £67 million in six months is a key risk factor; an analysis of the cash burn rate should be a primary focus in future reports to assess the company's financial runway.
• While the 20% rally is strong, consider that the stock is still trading at a fraction of its historical highs, suggesting the current move is a recovery within a long-term downtrend.